Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 54, Issue 14, Pages 5255-5259Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm200382r
Keywords
-
Categories
Funding
- University of Reading U.K.
- Reading School of Pharmacy
Ask authors/readers for more resources
Dopamine has previously been shown to inhibit angiogenesis in vitro and in vivo, but its clinical applications in this context are severely limited by its short half-life. Here we report the synthesis of a polyglutamic acid dopamine conjugate and show that conjugation significantly extends (from 1 to 24 h) dopamine's antiangiogenic activity in vitro and in vivo. These findings form the basis for the development of a new class of agents for the treatment of angiogenesis-dependent diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available